EternalBeing

GI MAP

£ 406.25

The Gastrointestinal Microbial Assay Plus (GI-MAP) assesses a patient’s microbiome from stool sample, with particular attention to microbes that may be disturbing normal microbial balance and contribute to perturbations in the GI flora.

Add to cart

Description
Additional info

The Gastrointestinal Microbial Assay Plus (GI-MAP)- Comprehensive panel of microbial targets, immune and digestive markers

The Gastrointestinal Microbial Assay Plus (GI-MAP) is an innovative clinical tool that measures gastrointestinal microbiota DNA from a single stool sample with state of the art, quantitative polymerase chain reaction (qPCR) technology.

The GI-MAP was designed to detect microbes that may be disturbing normal microbial balance or contributing to illness as well as indicators of digestion, absorption, inflammation, and immune function. With a culture based test it is not possible to measure strict anaerobes, viruses or virulence factors.

The GI-MAP's accuracy and reliability allows personalized protocols to address gut dysfunction based on which infections are urgent, which areas of the gut are already optimized, and which areas should be addressed after an infection is resolved. Additionally, the quantification of identified micro-organisms offers a remarkable ability to see how treatment modalities are working because a retest after treatment can show whether a parasite has resolved, dysbiosis has improved, and more.

Learn more about the GI-MAP in clinical practice by watching our webinar: https://www.youtube.com/watch?v=QL_ekGVOdaE

Indications

Autoimmune molecular mimicry (if caused by pathogens)
Diarrhea
Digestion
Foodborne illness
Gastritis
Gastroenteritis (if it has viral causes)
Gut dysbiosis
Immunity
Inflammation
Suspected bacterial, parasitic or viral pathogenesis (incl. detection of antibiotic resistant bacteria)

Overview

Overview

The Gastrointestinal Microbial Assay Plus (GI-MAP) was designed to assess a patient’s microbiome from a single stool sample, with particular attention to microbes that may be disturbing normal microbial balance and may contribute to perturbations in the gastrointestinal (GI) flora or illness. The panel is a comprehensive collection of microbial targets as well as immune and digestive markers. It screens for pathogenic bacteria, commensal bacteria, opportunistic pathogens, fungi, viruses, and parasites. It primarily uses multiplex, automated, DNA analysis to give integrative and functional medicine practitioners a better view into the gastrointestinal microbiome.

Methodology

Quantitative polymerase chain reaction (qPCR)

Analytes

BACTERIAL PATHOGENS

Campylobacter
C. difficile Toxin A
C. difficile Toxin B
Enterohemorrhagic E. coli
E. coli O157
Enteroinvasive E. coli/Shigella
Enterotoxigenic E. coli LT/ST
Shiga-like Toxin E. coli stx1
Shiga-like Toxin E. coli stx2
Salmonella
Vibro cholerae
Yersinia enterocolitica
H. pylori
- Virulence Factor, babA
- Virulence Factor, cagA
- Virulence Factor, dupA
- Virulence Factor, iceA
- Virulence Factor, oipA
- Virulence Factor, vacA
- Virulence Factor, virB
- Virulence Factor, virD

PARASITIC PATHOGENS

Cryptosporidium
Entamoeba histolytica
Giardia

VIRAL PATHOGENS

Adrenovirus 40/41
Norovirus GI
Norovirus GII

NORMAL/COMMENSAL BACTERIA

Akkermansia Mucinophilia
Bacteroides fragilis
Bifidobacterium spp.
Clostridia (class)
Enterobacter spp.
Enterococcus spp.
Escherichia spp.
Faecalbacterium prausnitzii
Lactobacillus spp.

BACTERIAL PHYLA

Bacteroidetes
Firmicutes
Firmicutes/Bacteroidetes Ratio

ADDITIONAL DYSBIOTIC/OVERGROWTH BACTERIA

Bacillus spp.
Enterococcus faecalis
Enterococus faecium
Morganella spp.
Pseudomonas spp.
Pseudomonas aeruginosa
Staphylococcus spp.
Staphylococcus aeureus
Streptococcus spp.
Methanobacteriaceae (family)

POTENTIAL AUTOIMMUNE TRIGGERS

Citrobacter spp.
Citrobacter freundii
Fusobacterium spp.
Klebsiella spp.
Klebsiella pneumoniae
Mycobacterium avium subsp. paratuberculosis
Prevotella spp
Proteus spp.
Proteus mirabilis

FUNGI/YEAST

Candida albicans
Candida spp.
Geotricum spp.
Microsporidia spp.
Rhodoturula spp.

OPPORTUNISTIC VIRUSES

CMV- Cytomegalovirus
EBV- Epstein Bar Virus

PARASITES & WORMS:

PROTOZOA

Blastocystis hominis
Chilomastix mesnelli
Cyclospora spp.
Dientamoeba fragilis
Endolimax nana
Entamoeba coli
Pentatrichomonas hominis

WORMS

Ancyclostroma duodenale
Ascaris lumbricoides
Necator americanis
Trichuris trichiura
Taenia spp

INTESTINAL HEALTH MARKERS:

DIGESTION

Elastase-1
Steatocrit

IMMUNE RESPONSE

SIgA
Anti-gliadin SIgA

INFLAMMATION

Calprotectin

GI MARKERS

ß-Glucuronidase
Occult Blood - FIT

ANTIBIOTIC RESISTANCE GENES (Optional add-on):

Phenotypes | HELICOBACTER

Amoxicillen
Clarithromycin
Fluroquinolines
Tetracycline

Practical

Specimen

Stool sample

Container

1x orange-capped stool vial

Patient preparation

Please refrain from taking aspirin for two days prior to collecting your sample.
Never discontinue prescription medication without first consulting your physician.

Age requirements

Can be used on all ages. However, often the microbiome of infants will appear very “dysbiotic”, as the microbiome and the infant’s immune system is very immature.

Available add-ons:

• Zonulin

Research

Abubakar I, Irvine L, Aldus CF, et al. A systematic review of the clinical, public health and costeffectiveness of rapid diagnostic tests for the detection and identification of bacterial intestinal pathogens in faeces and food. Health Technol Assess. 2007;11(36):1-216.
Amar CF, East CL, Gray J, Iturriza-Gomara M, Maclure EA, McLauchlin J. Detection by PCR of Eight groups of enteric pathogens in 4,627 faecal samples: re-examination of the English casecontrol Infectious Intestinal Disease Study (1993-1996). Eur J Clin Microbiol Infect Dis. 2007;26(5):311-323.
Bischoff SC, Barbara G, Buurman W, et al. Intestinal permeability — a new target for disease prevention and therapy. BMC gastroenterology. 2014;14:189.
Canny GO, McCormick BA. Bacteria in the intestine, helpful residents or enemies from within? Infection and immunity. 2008;76(8):3360-3373.
Fasano A, Shea-Donohue T. Mechanisms of disease: the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases. Nature clinical practice. 2005;2(9):416-422.
Iijima Y, Asako NT, Aihara M, Hayashi K. Improvement in the detection rate of diarrhoeagenic Bacteria in human stool specimens by a rapid real-time PCR assay. Journal of medical microbiology. 2004;53(Pt 7):617-622.
Kahlau P, Malecki M, Schildgen V, et al. Utility of two novel multiplexing assays for the detection of gastrointestinal pathogens - a first experience. SpringerPlus. 2013;2(1):106.
Kamada N, Seo SU, Chen GY, Nunez G. Role of the gut microbiota in immunity and inflammatory disease. Nature reviews. Immunology. 2013;13(5):321-335.
Khanna S, Tosh PK. A clinician's primer on the role of the microbiome in human health and disease. Mayo Clinic proceedings. 2014;89(1):107-114.
Othman M, Aguero R, Lin HC. Alterations in intestinal microbial flora and human disease. Current opinion in gastroenterology. 2008;24(1):11-16.
Rashid T, Ebringer A. Autoimmunity in Rheumatic Diseases Is Induced by Microbial Infections via Crossreactivity or Molecular Mimicry. Autoimmune diseases. 2012;2012:539282.
Schabereiter-Gurtner C, Hirschl AM, Dragosics B, et al. Novel real-time PCR assay for detection of Helicobacter pylori infection and simultaneous clarithromycin susceptibility testing of stool and biopsy specimens. Journal of clinical microbiology. 2004;42(10):4512-4518.
Stecher B, Hardt WD. The role of microbiota in infectious disease.Trends in microbiology. 2008;16(3):107-114.
Tiwana H, Wilson C, Walmsley RS, et al. Antibody responses to gut bacteria in ankylosing spondylitis, rheumatoid arthritis, Crohn's disease and ulcerative colitis. Rheumatology international. 1997;17(1):11-16.